DarioHealth (DRIO) Commences Public Offering of Common Stock

DarioHealth Corp. (Nasdaq: DRIO) ("DarioHealth" or the "Company"), a global digital therapeutics innovator, today announced that it intends to offer and sell shares of common stock (or pre-funded warrants in lieu thereof) in an underwritten public offering. The proposed offering is subject to market and other conditions, as well as customary closing conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the offering.

Craig-Hallum Capital Group is acting as sole managing underwriter for the offering.

DarioHealth intends to use the net proceeds of the offering for commercialization efforts for its products, such as increased marketing or production expenses, and for general working capital purposes.

The securities are being offered pursuant to an effective shelf registration statement on Form S-3 (File No. 333-212644) that was previously filed with the Securities and Exchange Commission (the "SEC"), and was declared effective on August 3, 2016.

You May Also Be Interested In

• FuelCell Energy prices $225M stock offering at $21 per share
• FuelCell Energy launches $200M common stock offering
• Comtech's Allerium president joins FirstNet Authority board